CVM
HEALTHCARECel-Sci Corp
$1.45-0.29 (-16.67%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving CVM Today?
No stock-specific AI insight has been generated for CVM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.44$13.48
$1.45
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-3.70
Dividend Yield—
Dividend / Share—
ROE-2.1%
Profit Margin—
Debt / Equity—
Trading
Volume837K
Avg Volume (10D)—
Shares Outstanding8.5M
CVM News
20 articles- CEL-SCI Reports Fiscal First Quarter 2026 ResultsYahoo Finance·Feb 18, 2026
- Cel-Sci: Fiscal Q1 Earnings SnapshotYahoo Finance·Feb 17, 2026
- CEL-SCI Reports Fiscal 2025 ResultsYahoo Finance·Dec 29, 2025
- CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025Yahoo Finance·Oct 20, 2025
- CEL-SCI Corporation to Present at LD Micro "Main Event" Investor ConferenceYahoo Finance·Oct 10, 2025
- CEL-SCI Announces Closing of $10 Million Public OfferingYahoo Finance·Aug 29, 2025
- CEL-SCI Announces Pricing of $10 Million Public OfferingYahoo Finance·Aug 28, 2025
- CEL-SCI Announces Proposed Public OfferingYahoo Finance·Aug 27, 2025
- CEL-SCI Reports Fiscal Third Quarter 2025 Financial ResultsYahoo Finance·Aug 14, 2025
- Cel-Sci: Fiscal Q3 Earnings SnapshotYahoo Finance·Aug 14, 2025
- CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA TimelineYahoo Finance·Aug 13, 2025
- CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American RulesYahoo Finance·Jul 14, 2025
- CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American RulesYahoo Finance·Jul 11, 2025
- CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck CancerYahoo Finance·Jul 11, 2025
- FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer PatientsYahoo Finance·Jun 18, 2025
- CEL-SCI Announces Closing of Public OfferingYahoo Finance·May 23, 2025
- CEL-SCI Announces Pricing of Public OfferingYahoo Finance·May 22, 2025
- CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ArabiaYahoo Finance·May 21, 2025
- CEL-SCI Announces Combination of Common StockYahoo Finance·May 19, 2025
- CEL-SCI Reports Fiscal Second Quarter 2025 Financial ResultsYahoo Finance·May 15, 2025
All 20 articles loaded
Price Data
Open$1.70
Previous Close$1.74
Day High$1.86
Day Low$1.50
52 Week High$13.48
52 Week Low$1.44
52-Week Range
$1.44$13.48
$1.45
Fundamentals
Market Cap$12M
P/E Ratio—
EPS$-3.70
Dividend Yield—
Dividend / Share—
ROE-2.1%
Profit Margin—
Debt / Equity—
Trading
Volume837K
Avg Volume (10D)—
Shares Outstanding8.5M
About Cel-Sci Corp
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—